Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Evaluation of MITF, SOX10, MART-1, and R21 Immunostaining for the Diagnosis of Residual Melanoma In Situ on Chronically Sun-Damaged Skin

Mu, Euphemia W., MD*,†; Quatrano, Nicola A., MD†,‡; Yagerman, Sarah E., MD; Ratner, Desiree, MD*; Meehan, Shane A., MD†,§

doi: 10.1097/DSS.0000000000001493
Original Article
Buy

BACKGROUND Melanocytic immunostains can assist in margin evaluation of melanoma in situ (MIS) excisions; however, their accuracy and reliability relative to hematoxylin & eosin (H&E) is yet to be determined.

OBJECTIVE The objective of this study was to evaluate the sensitivity, specificity, and concordance of 4 melanocyte-specific immunostains for diagnosing MIS occurring on chronically sun-damaged skin.

MATERIALS AND METHODS Serial permanent sections from representative areas of negative margin and residual tumor were stained using H&E, MITF, MART-1, SOX10, and R21 and examined in a blinded fashion. The study set included 100 digital microscopy images from 10 cases of MIS excisions from the face. Two board-certified dermatopathologists, 4 fellowship-trained Mohs surgeons, 2 Mohs fellows, and 2 dermatology residents independently reviewed the 100 images.

RESULTS The average melanocyte density was 11 versus 28 melanocytes per 0.5 mm for chronically sun-damaged skin versus residual MIS on H&E, respectively. Statistically significantly higher melanocyte densities were observed using MITF, MART-1, and SOX10 on negative margins. The sensitivity and interobserver concordance was highest using MITF and SOX10. The intraobserver agreement on 4 duplicate images was 85%.

CONCLUSION In conclusion, the nuclear immunostains (MITF and SOX10) show the most promise for improving the diagnosis of MIS in chronically sun-damaged skin.

*Mount Sinai Beth Israel Dermatologic Oncology, New York, New York;

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York;

SkinCare Physicians, Chestnut Hill, Massachusetts;

§Department of Pathology, Dermatopathology Section, New York University School of Medicine, New York, New York

Address correspondence and reprint requests to: Shane A. Meehan, MD, Department of Pathology, Dermatopathology Section, New York University School of Medicine, 240 E. 38th Street, 11th Floor, New York, NY 10016, or e-mail: shane.meehan@nyumc.org

The authors have indicated no significant interest with commercial supporters.

IRB approval status: reviewed by the New York University School of Medicine's Institutional Review Board, Study #s16-01701.

© 2018 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website